Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2018-004459-19-DE
EUCTR2018-004459-19-DEActive, not recruitingPhase 1

An open label, multi-center roll-over study to assess long-term effect in pediatric patients treated with Tafinlar (dabrafenib) and/or Mekinist (trametinib)

ovartis Pharma AG0 sites250 target enrollmentStarted: July 6, 2022Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Enrollment
250
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •Subjects eligible for inclusion in this study must meet all of the following criteria:
  • •All subjects
  • •1. Written informed consent, according to local guidelines, signed by the patients and / or by the parents or legal guardian prior to any study related screening procedures are performed.
  • •2. Participation in a Novartis sponsored study such as TMT212X2101, DRB436G2201, DRB436A2102, regardless of current age
  • •3. Parent study (or cohort of parent study) is planned to be closed
  • •4. Patient has demonstrated treatment compliance, as assessed by the Investigator, within the parent study protocol requirement(s).
  • •5. Willingness and ability to comply with scheduled visits, treatment plans and any other study procedures.
  • •For Subjects Entering the Treatment Period
  • •6. Patient is currently receiving treatment with dabrafenib/trametinib monotherapy or combination within a Novartis Sponsored Drug Development study.
  • •7. In the opinion of the Investigator, the subject is likely to benefit from continued treatment.
  • •8. Does not require treatment with prohibited concomitant medications.
  • •Are the trial subjects under 18? yes
  • •Number of subjects for this age range: 250
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 50
  • •F.1.3 Elderly (>=65 years) no
  • •F.1.3.1 Number of subjects for this age range

Exclusion Criteria

  • •1. Patient has participated in a combination trial where dabrafenib and/or trametinib was dispensed in combination with another study medication. (Exception: Patients who were on the chemotherapy arm of the CDRB436G2201 study are eligible for this study after crossing over into the experimental treatment arm of the CDRB436G2201 study or have discontinued the study treatment and are now in follow-up)
  • •2. Patient has permanently discontinued from study treatment in the parent protocol due to any reason.
  • •3. Treatment with dabrafenib and/or trametinib for the patient’s indication is approved for marketing and the appropriate dosage form is commercially available and reimbursed in the local country
  • •4. Patient currently has unresolved drug related severe toxicities for which dabrafenib and/or trametinib dosing has been interrupted in the parent study. If the patient should meet criteria to resume treatment on the parent protocol then they may be eligible for enrolment in this study.
  • •5. Women of childbearing potential, defined as all females physiologically capable of becoming pregnant, must continue to use highly effective form of birth control method (contraception) during the study and for 16 weeks after stopping treatment with trametinib monotherapy or dabrafenib in combination with trametinib, and 2 weeks after stopping treatment with dabrafenib monotherapy, whichever is longer.
  • •a. Total abstinence (when this is in line with the preferred and usual lifestyle of the subject). Periodic abstinence (i.e. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
  • •b. Female sterilization, surgically sterilized prior to the study (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when reproductive status of woman has been confirmed by follow-up hormone level assessment.
  • •c. Sterilization (at least 6 months prior to screening) for male partners. The sterilized male partner should be the sole partner for that subject.
  • •d. For subjects on dabrafenib monotherapy / trametinib in combination with dabrafenib: Placement of a hormonal or non-hormonal intrauterine device (IUD) or intrauterine system (IUS) with a documented failure rate of less than 1% per year.
  • •e. For subjects on trametinib monotherapy: Use of oral (estrogen and progesterone) injected or implanted combined hormonal methods of contraception, or placement of an intrauterine device (IUD), or intrauterine system (IUS), or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception.
  • •Male subjects (including those that have had a vasectomy) not willing to use a condom during intercourse while taking trametinib and/or dabrafenib and not to father a child during the study and for the period of 16 weeks (for patients taking trametinib only, or in combination) or 2 weeks (for patients taking dabrafenib only) following stopping of study treatment.
  • •6. Lactating females who are actively breast feeding.
  • •7. Concurrent participation in other clinical trials using experimental therapies

Investigators

Similar Trials

Active, not recruiting
Phase 1
This clinical study is designed to provide continued access to pediatric patients who have previously participated in a dabrafenib and/or trametinib study and who in the opinion of the Investigator, would benefit from continued treatment
EUCTR2018-004459-19-NLovartis Pharma AG250
Not yet recruiting
Phase 4
An open label, multi-center roll-over study to assess long-term effect in pediatric patients treated with Tafinlar (dabrafenib) and/or Mekinist (trametinib)
NL-OMON51275ovartis3
Recruiting
Phase 4
An open label, multi-center roll-over study to assess long-term safety in patients who are ongoing or have completed a prior global Novartis or GSK sponsored Tafinlar (dabrafenib) and/or Mekinist (trametinib) study and are judged by the investigator to benefit from continued treatmentvarious rare malignant tumors10027655
NL-OMON51217ovartis3
Active, not recruiting
Phase 1
This clinical study is designed to provide continued access to patients who have previously participated in a dabrafenib and/or trametinib study and who in the opinion of the Investigator, would benefit from continued treatmentPatients with BRAF V600 mutation positiveMedDRA version: 20.0Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2017-001987-39-NLovartis Pharma AG78
Active, not recruiting
Phase 1
This clinical study is designed to provide continued access to pediatric patients who have previously participated in a dabrafenib and/or trametinib study and who in the opinion of the Investigator, would benefit from continued treatmentChildren and Adolescents with Cancers Harboring V600 mutations
EUCTR2018-004459-19-FIovartis Pharma AG250